A study on side effects such as nausea and vomitus after medication to prevent excessive bleeding after a caesarean section

| Submission date | Recruitment status No longer recruiting | Prospectively registered | |
|-------------------|--|--|--|
| 03/02/2013 | | Protocol | |
| Registration date | Overall study status | Statistical analysis plan | |
| 28/02/2013 | Completed | [X] Results | |
| Last Edited | Condition category | Individual participant data | |
| 07/03/2018 | Pregnancy and Childbirth | | |

Plain English summary of protocol

Background and study aims

At the end of a cesarean section in Belgium, in general some medication is given to the mother to prevent excessive bleeding. The two products used most frequently are called carbetocin and oxytocin and work well. No difference has been demonstrated as far as the effect on prevention of bleeding is concerned. A major side effect of this kind of medication is nausea and vomitus and a lowering of blood pressure resulting in dizziness. The aim of the present study is to compare nausea, vomiting and changes in blood pressure between carbetocin and oxytocin.

Who can participate?

Any pregnant woman for whom a caesarean section is planned in a term (full grown) pregnancy without any other complication can participate.

What does the study involve?

Participants are randomly allocated to one of two groups. All women receive an intravenous medication to prevent bleeding and no one (participant, operating or treating team) will not know whether the medication used is carbetocin or oxytocin.

What are the possible benefits and risks of participating?

There is no difference with routine management during which both medications are used. The results of this study will help future patients to receive the product with the fewest side effects.

Where is the study run from?

The study will be run in the Obstetrics Ward at Antwerp University Hospital UZA, Belgium.

When is the study starting and how long is it expected to run for? The study will be running for one year and will start in March 2013.

Who is funding the study?

This study is not funded by any pharmaceutical company, all costs are taken care of by the local Fund for perinatal Medicine of the Department of Obstetrics at Antwerp University Hospital

Who is the main contact? Prof Dr Yves Jacquemyn Yves.jacquemyn@uza.be

Contact information

Type(s)

Scientific

Contact name

Prof Yves Jacquemyn

Contact details

Wilrijkstraat 10 Edegem Belgium 2650

_

yves.jacquemyn@uza.be

Additional identifiers

Protocol serial number

OBGYN-1

Study information

Scientific Title

OBGYN-1: A randomized controlled trial on nausea, vomitus and blood pressure changes comparing carbetocine versus oxytocine in the prevention of hemorrhage after caesarean section

Acronym

NAVOCASY

Study objectives

Single shot intraveneous carbetocin is accompanied with more nausea and vomitus as compared to intravenous oxytocin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee Ethisch Comité Universitair Zieknhusi Antwerpen, 21/02/2011, ref: B300201110299

Study design

Prospective randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pregnancy and delivery

Interventions

Standard intravenous carbetocin vs standard intravenous oxytocin

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Carbetocin, oxytocin

Primary outcome(s)

From the moment the participant enters the operating theatre until one hour later, blood pressure and heart frequence are carefully registered every 5 minutes or more as during routine monitoring of surgery. Nausea and vomitus are evaluated before surgery (just before incision), during surgery: before giving the intravenous medication and after 5, 10 and 15 minutes based on the standardized scale:

0: no nausea, no vomitus

1: mild nausea, no vomiting

2: nausea but with retching, no vomiting

3: nausea and vomiting

Key secondary outcome(s))

Any other complaint

Completion date

15/02/2014

Eligibility

Key inclusion criteria

Term uncomplicated pregnant women who undergo a planned cesarean section

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

- 1. Unplanned caesarean section
- 2. Complications including: hypertension, preterm labour, any gastrointestinal or cardiovascular disease necessitating treatment

Date of first enrolment

15/02/2013

Date of final enrolment

15/02/2014

Locations

Countries of recruitment

Belgium

Study participating centre Antwerp University Hospital

Edegem Belgium 2650

Sponsor information

Organisation

Antwerp University Hospital (Belgium)

ROR

https://ror.org/01hwamj44

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Department of Obstetrics, Antwerp University Hospital (Belgium)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

| Output type | Details | Date created Date added Peer reviewed? Patient-facing? | | |
|-------------------------------|-------------------------------|--|----------|-----|
| Results article | results | 02/01/2018 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 11/11 | /2025 No | Yes |